Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Yu Zhou¹, Jiang Wang¹, Zhanni Gu¹, Shuni Wang¹, Wei Zhu¹, José Luis Aceña^{2

3}, Vadim A Soloshonok^{2

4}, Kunisuke Izawa⁵, Hong Liu¹

Affiliations

¹ Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, China.
² Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU , Paseo Manuel Lardizábal 3, 20018 San Sebastián, Spain.
³ Department of Organic Chemistry, Autónoma University of Madrid , Cantoblanco, 28049 Madrid, Spain.
⁴ IKERBASQUE, Basque Foundation for Science, María Díaz de Haro 3, 48013 Bilbao, Spain.
⁵ Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka, Japan 533-0024.

Review

Yu Zhou et al. Chem Rev. 2016.

. 2016 Jan 27;116(2):422-518.

doi: 10.1021/acs.chemrev.5b00392. Epub 2016 Jan 12.

Yu Zhou¹, Jiang Wang¹, Zhanni Gu¹, Shuni Wang¹, Wei Zhu¹, José Luis Aceña^{2

3}, Vadim A Soloshonok^{2

4}, Kunisuke Izawa⁵, Hong Liu¹

¹ Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, China.
² Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU , Paseo Manuel Lardizábal 3, 20018 San Sebastián, Spain.
³ Department of Organic Chemistry, Autónoma University of Madrid , Cantoblanco, 28049 Madrid, Spain.
⁴ IKERBASQUE, Basque Foundation for Science, María Díaz de Haro 3, 48013 Bilbao, Spain.
⁵ Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka, Japan 533-0024.

No abstract available

Publication types